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AbstrACt
Objective To estimate the population prevalence of 
anxiety disorders during pregnancy and investigate the 
diagnostic accuracy of the two-item Generalised Anxiety 
Disorder scale (GAD-2) for a) GAD and b) any anxiety 
disorder.
Design Cross-sectional survey using a stratified sampling 
design. Sampling weights were used in the analysis to 
adjust for the bias introduced by the stratified sampling.
setting Inner-city maternity service, South London.
Participants 545 pregnant women were interviewed after 
their first antenatal appointment; 528 provided answers on 
the GAD-2 questions.
Main outcome measures Diagnosis generated by the 
Structured Clinical Interview for Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition (SCID).
results Population prevalence of anxiety disorders 
was 17% (95% CI 12% to 21%): 5% (95% CI 3% to 6%) 
for GAD, 4% (95% CI 2% to 6%) for social phobia, 8% 
(95% CI 5% to 11%) for specific phobia and 2% (95% 
CI 1% to 4%) for obsessive-compulsive disorder. Post-
traumatic stress disorder (PTSD) prevalence was unclear 
due to higher levels of reluctance to respond to PTSD 
interview questions but sensitivity analyses suggest 
population prevalence maybe up to 4% (95% CI 2% to 
6%). Weighted sensitivity of GAD-2 for GAD (cut-off ≥3) 
was 69%, specificity 91%, positive predictive value 26%, 
negative predictive value 98% and likelihood ratio 7.35. 
For any anxiety disorder the weighted sensitivity was 26%, 
specificity 91%, positive predictive value 36%, negative 
predictive value 87% and likelihood ratio 2.92.
Conclusions Anxiety disorders are common but GAD-2 
generates many false positives and may therefore be 
unhelpful in maternity services.
IntrODuCtIOn  
Anxiety disorders are more common in 
women than men,1 2 and the perinatal period 
(ie, pregnancy and the year after birth) has 
been reported as a particularly vulnerable 
time for the onset or relapse of anxiety disor-
ders in women.3 4 Antenatal anxiety disorders 
have been associated with adverse pregnancy 
outcomes, including preterm birth, low birth 
weight, lower Apgar scores, postpartum 
anxiety and depression and adverse child 
developmental outcomes5–7 including diffi-
cult temperament, increased sleep problems, 
bonding/attachment problems and poorer 
emotional, behavioural and cognitive devel-
opment.5–10 A recent systematic review and 
meta-analysis reported a pooled prevalence of 
4% (95% CI 2% to 6%; 10 studies with pooled 
n=6910) for Generalised Anxiety Disorder 
(GAD) and 15% (95% CI 9% to 21%; 9 
studies with pooled n=4648) for any anxiety 
disorders during pregnancy based on studies 
conducted outside of the UK where diag-
nostic clinical interviews were used, and 
23% when using cut-offs on validated self-re-
port questionnaires.11 Anxiety disorders are 
treatable, so early detection and treatment 
during the antenatal period, when women 
are in regular contact with healthcare profes-
sionals could prevent adverse outcomes.12–14 
However, despite regular contact with health-
care professionals during pregnancy, ante-
natal mental disorders are often undetected 
and untreated.15 16 
strengths and limitations of this study
 ► This study investigates the effectiveness of the two-
item Generalised Anxiety Disorder scale (GAD-2) in 
identifying antenatal anxiety disorders—a method 
suggested by the National Institute for Health and 
Care Excellence (CG192 2014) on the basis of expert 
consensus rather than research evidence.
 ► We recruited a representative sample of women us-
ing an efficient and robust sampling design, which 
facilitated the estimation of population prevalences.
 ► We used a gold standard diagnostic interview.
 ► This research was limited to recruitment from a 
single maternity site in London, although the single 
South London maternity site used was a very ethni-
cally and socioeconomically diverse population.
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The National Institute for Health and Care Excel-
lence (NICE) (CG192; 2014) suggested that maternity 
professionals could consider the use of the two-item 
GAD tool (GAD-2) to identify anxiety disorders during 
pregnancy and after birth, although also highlighted 
the lack of evidence on the use of the GAD-2 in early 
pregnancy. The recommendation was therefore driven 
by concern about the high prevalence of anxiety disor-
ders (NICE 2014).12 17 This extends the focus of early 
intervention from a previous emphasis on identification 
of perinatal depression to other perinatal mental disor-
ders, including comorbid conditions. Outside of the 
perinatal period, a systematic review and meta-analysis18 
of studies in men and women reported that the GAD-2 
(using a cut-off of ≥3) showed fairly high pooled sensi-
tivity of 0.76 (95% CI 0.55 to 0.89), and pooled speci-
ficity of 0.81 (95% CI 0.60 to 0.92) for GAD (five studies 
with pooled n=1987). For detecting any anxiety disorder, 
the systematic review18 reported a moderate sensitivity 
(range: 0.65–0.72) and unclear specificity (range: 0.39–
0.92) (three studies, n=1225). The diagnostic accuracy 
of the GAD-2 questions in identifying anxiety disorders 
during early pregnancy remains unstudied. As women 
in early pregnancy are likely to have many anxieties (eg, 
over the viability of the pregnancy, decisional conflict 
over unplanned pregnancies), there may be high rates 
of ‘false positives’ when using the GAD-2 in pregnancy 
which could result in inappropriate referrals to mental 
health services.
We therefore aimed to investigate:
1. The UK prevalence of GAD, other anxiety disorders 
(including panic disorder, agoraphobia without panic 
disorder, social phobia, specific phobia, obsessive-com-
pulsive disorder (OCD) and post-traumatic stress dis-
order (PTSD)) and comorbidity with other mental 
disorders during early pregnancy.
2. The sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), positive likeli-
hood ratio (LR+) and negative likelihood ratio (LR−) 
of the GAD-2 screening questions (on a Likert scale) 
compared with a gold standard diagnostic interview 
(Diagnostic and Statistical Manual of Mental Disor-
ders, 4th edition (DSM-IV))19 for identifying GAD, 
and for identifying any anxiety disorders (including 
panic disorder, agoraphobia without panic disorder, 
social phobia, specific phobia, OCD, PTSD and GAD) 
during early pregnancy. As DSM-V20 no longer catego-
rises OCD or PTSD as anxiety disorders, we also inves-
tigated diagnostic accuracy for any anxiety disorders by 
excluding OCD and PTSD.
3. How the sensitivity, specificity, PPV, NPV, LR+ and LR− 
change when the GAD-2 is scored and categorised as a 
yes (cut-off 1 or more) verses no (score of 0) response 
instead of the conventional cut-off of 3 or more (which 
could be asked by midwives at the same time as the two 
depression screening questions).
MethODs
study design and participants
The WEll-being in pregNancy stuDY (WENDY study) was 
a cross-sectional survey that recruited women from an 
inner-city maternity service in South-east London using a 
sampling design stratified according to answering positive 
or negative (saying yes or no, respectively) on either of 
the two Whooley questions which are routinely asked by 
midwives as a mental health screen during the first ante-
natal booking appointment ("During the past month have 
you often been bothered by feeling down, depressed or 
hopeless?”; "During the past month have you often been 
bothered by having little interest or pleasure in doing 
things?”). A random sample of Whooley negative and all 
Whooley positive women were invited to participate.
Exclusion criteria were women aged under 16 years, 
women who declined to answer Whooley questions, those 
who had a termination or miscarriage prior to baseline 
interview or had already attended for their maternity 
booking appointment elsewhere in the UK. Eligible preg-
nant women who agreed to participate were recruited 
into the study as soon as possible after their first antenatal 
booking appointment, within a maximum of 3 weeks 
from the original booking appointment. Data collection 
of the index test (GAD-2 measure) and reference test 
(the gold standard diagnostic interview) were performed 
during the research interview, after written informed 
consent was obtained. Language interpreters were used 
where needed. For further details and power calculation 
of the WENDY study, see Howard et al.21 Sample size of 
the current analysis was determined by the number of 
women with available data on the index test (GAD-2). 
Figure 1 shows flow chart of women through the WENDY 
study and those used for the current analysis.
research measures
GAD-2: This is a subscale of the Generalised Anxiety 
Disorder scale GAD-7 measure22 and is a two-item self-re-
port screen completed by women during the research 
interview. The questions include “Over the last 2 weeks, 
how often have you been bothered by any of the following 
problems? 1) Feeling nervous, anxious or on edge; 2) 
not being able to stop or control worrying”. Answers are 
given on a Likert scale (not at all=0, several days=1, more 
than half the days=2 and nearly everyday=3). Scores range 
from 0 to 6, with a cut-off score of 3 or more indicative of 
anxiety symptoms.23 The GAD-2 has also been used where 
YES to either question categorises an individual as a posi-
tive screen (used in clinical practice),24 thus a score of 
1 or more would indicate a possible YES answer. In this 
study, women’s responses to the GAD-2 questions were 
categorised into the following groups:
1. GAD-2 (≥3): GAD-2 positive if they scored 3 or more 
(conventional scoring method), GAD-2 negatives if 
they scored <3.
2. GAD-2 (yes/no): GAD-2 positive if they scored 1 or 
more (indicating a ‘yes’ to either question), which is 
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used more in clinical practice, GAD-2 negative if scor-
ing 0 (indicating ‘no’ to both questions).
Anxiety disorders and comorbid disorders
The Structured Clinical Interview for DSM-IV Axis I 
Disorders (SCID-I): the SCID is a researcher-adminis-
tered, semi-structured, and gold standard diagnostic 
interview consisting of standardised questions that corre-
spond to each DSM-IV Axis I criteria.19 We used the mood 
and anxiety disorders modules to generate diagnosis of 
depression, GAD, panic disorder, agoraphobia without 
panic disorder, social phobia, specific phobia, OCD 
and PTSD. Consensus on diagnosis was achieved during 
researcher’s weekly meetings with LMH. Although clinical 
information and GAD-2 data were available at the time 
of these meetings, agreement on diagnosis was reached 
using responses given by women during the SCID inter-
views (ie, the GAD-2 items were not used to determine 
diagnosis of anxiety disorders).
As DSM-V20 does not categorise OCD or PTSD as 
anxiety disorders and as the research version of the SCID 
for DSM-V was released after the start of the current study, 
we also carried out analyses for any anxiety disorders 
Figure 1 Flow chart of women through the WEll-being in pregNancy stuDY (WENDY) study during the study period (total 
recruited n=545) and women with available data on the two-item Generalised Anxiety Disorder scale (GAD-2) (n=528).
 o
n
 18 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023766 on 5 September 2018. Downloaded from 
4 Nath S, et al. BMJ Open 2018;8:e023766. doi:10.1136/bmjopen-2018-023766
Open access 
according to those included in DSM-V as anxiety disor-
ders, that is, excluding OCD and PTSD. We also used the 
eating disorder module to generate diagnosis for eating 
disorders including anorexia nervosa (including atyp-
ical), bulimia nervosa, binge eating disorder, purging 
disorder and other eating disorder.
Patient involvement
The development of the WENDY study, outcome measures, 
grant application and study protocol were informed by 
our patient and carer advisory group. Meetings were held 
every few months to discuss the WENDY study and other 
related studies within a programme of work funded by 
the National Institute for Health Research (https://www. 
kcl. ac. uk/ ioppn/ depts/ hspr/ research/ CEPH/ wmh/ 
projects/ A- Z/ esmi. aspx). The patient advisory group 
includes women with a range of mental disorders and 
have interest in our study programme. We circulated 
the results and draft manuscript (see 'Acknowledge-
ments' section) to members of the group for comments. 
Patients were not involved in the recruitment or conduct 
of the study.
statistical analysis
Data were managed and analysed using Stata V.15.25 
Sampling weights were used to adjust for the oversampling 
of Whooley positive women26 in all analyses apart from 
examining differences in sociodemographics between 
GAD-2 positives and GAD-2 negatives. The population 
prevalence of anxiety disorders and comorbid disorders 
were estimated based on weighted diagnostic interview 
responses (using Stata’s ‘svy’ command). Bootstrap resa-
mpling of the weighted estimators was used for calcula-
tion of CIs.
As prespecified in our analysis plan, the weighted rates 
of ‘true positive’, ‘false positives’, ‘true negatives’ and 
‘false negatives’ were tabulated for GAD, any anxiety 
disorder (including PTSD and OCD) and any anxiety 
disorder (without PTSD or OCD). Using these values, 
the sensitivity, specificity, PPV, NPV and LRs (positive and 
negative) were calculated.
Missing data
Of the 545 participants, 24 (4%) women had some SCID 
missing data: one participant on GAD and all eating disor-
ders: 1 participant on agoraphobia, specific phobia and 
PTSD; 1 participant on mixed anxiety and depression, 
borderline personality disorder and PTSD; 1 participant 
on hypomanic, manic, current major depressive disorder 
and bipolar I and II; 1 participant on all eating disorders 
and 19 participants on the PTSD module. List-wise dele-
tion (performed in Stata) was used to calculate frequen-
cies of SCID disorders in the study sample.
To calculate population prevalence of the SCID 
disorders, missing observations in the SCID items were 
accounted for by using inverse probability weights that 
incorporated the Whooley sampling, as well as variables 
that were significant in predicting missingness of SCID 
responses (for full details of weightings and analysis 
strategy, see Howard et al26). Due to the large numbers 
of women who declined to respond to questions on the 
PTSD module, we carried out a sensitivity analysis for the 
prevalence estimate of PTSD in which we first assumed 
that all missing data were actually cases of PTSD, and then 
assumed that all missing data were not cases of PTSD.
Seventeen participants (3%) had missing GAD-2 data 
(15 for both questions, 1 for GAD-2 question 1 and 1 
for GAD-2 question 2). No imputation was performed 
for women with missing data on GAD-2 items because 
missing data for one question would mean 50% data 
missing. These were therefore treated as missing obser-
vations and only women with complete data on both 
GAD-2 questions were used in the analyses to investigate 
sensitivity and specificity (n=528). Out of 528 women with 
complete data on the GAD-2 questions, there was missing 
data on the following SCID anxiety modules: 1 partici-
pant had missing data on PTSD, agoraphobia and specific 
phobia and 18 participants had missing data on the PTSD 
module.
ethics approval
The participants were provided with study information 
sheets, which was fully explained to them, had the oppor-
tunity to ask questions and gave informed consent prior 
to taking part in the study. No adverse events occurred 
for women taking part in the study during the research 
interview. Where risk (eg, significant suicidality, safe-
guarding issues) was identified during the research inter-
view, researchers discussed this with the study PI and the 
woman’s midwife and/or GP were informed, following 
consent to information sharing by the study participant 
(all women were aware this occurred and consented to 
this).
results
sample characteristics
Between the dates of 10 November 2014 and 30 June 2016, 
10 004 women attended their initial antenatal booking 
appointment with a midwife at the study site. Of these 
women, 41 did not have Whooley answers recorded so 
the base population consisted of 9963 women. The total 
number of eligible women recruited into the WENDY 
study was 545 women. This sample was similar to the base 
population on sociodemographic factors such as age, 
ethnicity and number of children.21 Of the total number 
of women recruited into the WENDY study, 528 (97%) 
provided answers to the GAD-2 questions (figure 1). Socio-
demographic characteristics (age, ethnicity and number 
of children) of women that provided GAD-2 answers were 
similar to the rest of the WENDY sample and wider base 
population (see online supplementary file 1). There were 
119 (23%) GAD-2 (≥3) positives and 409 (77%) GAD-2 
(<3) negatives within our study sample, where GAD-2 
(≥3) positive was defined as reporting a total score of 3 or 
more on the GAD-2 questions (table 1). Compared with 
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Table 1 Sociodemographics and characteristics of participants with GAD-2 data included in the diagnostic accuracy 
analyses (n=528)
GAD-2
negative
score<3
n=409
GAD-2
positive
score≥3
n=119 P values
Overall (total)
n=528
Age (years) 0.126
  16–19 4 (1%) 3 (3%) 7 (1%)
  20–29 104 (25%) 40 (34%) 144 (27%)
  30–39 267 (65%) 69 (58%) 336 (64%)
  40+ 34 (8%) 7 (6%) 41 (8%)
Ethnicity 0.384
  White 223 (55%) 56 (47%) 279 (53%)
  Black/Caribbean 123 (30%) 46 (39%) 169 (32%)
  Asian/Asian British 19 (5%) 3 (3%) 22 (4%)
  Mixed/multiple ethnicity 17 (4%) 5 (4%) 22 (4%)
  Other 27 (7%) 9 (8%) 36 (7%)
Highest education level 0.006
  None/school qualifications 38 (9%) 24 (20%) 62 (12%)
  College/diploma/higher/certificate/training 147 (36%) 42 (35%) 189 (36%)
  Degree level/postgraduate qualifications 224 (55%) 53 (45%) 277 (52%)
Employment status* 0.010
  Employed 271 (66%) 69 (58%) 340 (65%)
  Student 19 (5%) 2 (2%) 21 (4%)
  Unemployed 42 (10%) 19 (16%) 61 (12%)
  Homemaker 58 (14%) 14 (12%) 72 (14%)
  Not working due to illness/other 18 (4%) 14 (12%) 32 (6%)
Income† <0.001
 <£15 000 41 (13%) 32 (35%) 73 (18%)
  £15 000–£30 999 54 (17%) 16 (17%) 70 (17%)
  £31 000–£45 999 50 (16%) 10 (11%) 60 (15%)
  £46 000–£60 999 52 (16%) 10 (11%) 62 (15%)
  £61 000 or more 119 (38%) 24 (26%) 143 (35%)
Relationship status <0.001
  Single 34 (8%) 23 (19%) 57 (11%)
  Partner but not cohabiting 57 (14%) 22 (18%) 79 (15%)
  Married/cohabiting 313 (77%) 70 (59%) 383 (72%)
  Separated/divorced 5 (1%) 4 (3%) 9 (2%)
Multiparous
  No 202 (49%) 62 (52%) 0.603 264 (50%)
  Yes 207 (51%) 57 (48%) 264 (50%)
Planned pregnancy
  Yes 280 (68%) 67 (56%) 0.014 347 (66%)
Late booker
  Yes 344 (84%) 94 (79%) 0.191 438 (83%)
Translator required
  Yes 25 (6%) 13 (11%) 0.074 38 (7%)
*Two participants had missing data on employment status (1 GAD-2 positive and 1 GAD-2 negative).
†One hundred twenty participants had missing data on income (93 GAD-2 negatives, 27 GAD-2 positives).
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GAD-2 negatives, GAD-2 positives were more likely to be 
single, have lower levels of education, be unemployed or 
not working due to illness, have a lower income and have 
an unplanned pregnancy. When scoring for GAD-2 posi-
tives was defined as scoring 1 or more, there were 226 
(43%) GAD-2 (yes/no) positives and 302 (57%) GAD-2 
(yes/no) negatives within our study sample.
sCID anxiety disorder prevalence and comorbidity
Using weighted estimates, the population prevalence was 
estimated as 17% (95% CI 12% to 21%) for any SCID 
anxiety disorder (or 15% (95% CI 11% to 19%) for any 
SCID anxiety disorder excluding PTSD and OCD, as 
in DSM-V). Specifically, there was an estimated popu-
lation prevalence of 5% (95% CI 3% to 6%) for GAD, 
4% (95% CI 2% to 6%) for social phobia, 8% (95% CI 
5% to 11%) for specific phobia, 0.2% (95% CI 0.03% to 
0.3%) for panic disorder, 0.4% (95% CI 0% to 2%) for 
agoraphobia, 2% (95% CI 1% to 4%) for OCD and 0.8% 
(95% CI 0% to 1%) for PTSD. As missing data were partic-
ularly common for the PTSD module, a sensitivity analysis 
demonstrated that when all women with missing data are 
assumed to have PTSD, the population prevalence esti-
mate was 4% (95% CI 2% to 6%). When all women with 
missing data are assumed not to have PTSD, the popu-
lation prevalence estimate was 0.8% (95% CI 0.1% to 
1.4%). Of note, of the women who declined to respond 
to the PTSD questions, eight had already disclosed severe 
trauma earlier during the research interview which were 
related to being physically abused, sexual abuse/rape and 
witnessing violence.
The estimated population prevalence of comorbid 
depression with any anxiety disorder was 5% (95% CI 
2% to 7%) (or 4% (95% CI 2% to 6%) for comorbid 
depression and any anxiety disorder excluding PTSD and 
OCD). Comorbid depression and GAD was estimated as 
2% (95% CI 1% to 3%). Table 2 presents unweighted 
count (%) and weighted estimates of population preva-
lence (%) of comorbidity between SCID depression and 
all anxiety disorders (including PTSD and OCD).
Diagnostic accuracy of the GAD-2 screening questions in 
identifying GAD
SCID GAD was found in 23 (6%) of GAD-2 (<3) nega-
tive and 35 (29%) of GAD-2 (≥3) positive women. After 
adjusting for weights, GAD was estimated to occur in 137 
(2%, 95% CI 1% to 3%) of GAD-2 (<3) negatives and 
302 (26%, 95% CI 15% to 40%) of GAD-2 (≥3) positives. 
SCID GAD was not found in 8439 (98%, 95% CI 97% to 
99%) GAD-2 (<3) negatives and 872 (74%, 95% CI 60% 
to 85%) GAD-2 (≥3) positives (see online supplemen-
tary files 2 and 3 for cross-tabulation and proportions). 
Weighted sensitivity was 0.69, specificity 0.91, PPV 0.26, 
NPV 0.98, LR+ 7.35 and LR− 0.34. When scoring of the 
GAD-2 was changed to ≥1 (yes/no response), 58 (19%) 
of GAD-2 (yes/no) positive women met criteria for SCID 
GAD, whereas there were no GAD-2 (yes/no) negative 
women that met criteria for SCID GAD. After adjusting 
for weights, SCID GAD was estimated in 439 (11%, 95% CI 
7% to 16%) of GAD-2 (yes/no) positives, whereas 5633 
(100%) of GAD-2 (yes/no) negatives and 3678 (89%, 
95% CI 84% to 93%) GAD-2 (yes/no) positives did not 
meet criteria for SCID GAD (see online supplementary 
files 2 and 4 for cross-tabulation and proportions). The 
weighted sensitivity was 1, specificity 0.60, PPV 0.11, NPV 
1, LR+ 2.53 and LR− 0.
Diagnostic accuracy of the GAD-2 screening questions in 
identifying any anxiety disorder
SCID anxiety disorders (including GAD, PTSD and OCD) 
were found in 73 (18%) of GAD-2 (<3) negatives and 57 
(50%) of GAD-2 (≥3) positive women. After adjusting 
for weights, an estimated 1125 (13%, 95% CI 10% to 
18%) of GAD-2 (<3) negatives and 404 (36%, 95% CI 
23% to 51%) of GAD-2 (≥3) positives met criteria for 
any SCID anxiety disorder (including PTSD and OCD). 
SCID anxiety disorders were not found in 7268 (87%, 
95% CI 82% to 90%) GAD-2 (<3) negatives and 723 
(64%, 95% CI 49% to 77%) GAD-2 (≥3) positives (see 
online supplementary files 5 and 6 for cross-tabulation 
and proportions). Weighted sensitivity was 0.26, speci-
ficity 0.91, PPV 0.36, NPV 0.87, LR+ 2.92 and LR− 0.81. 
When scoring of the GAD-2 was changed to ≥1 (yes/no 
response), 22 (10%) of GAD-2 (yes/no) negative and 108 
(37%) of GAD-2 (yes/no) positive women met criteria for 
any anxiety disorder (including PTSD and OCD). After 
adjusting for weights, 453 (8%, 95% CI 5% to 13%) of 
GAD-2 (yes/no) negatives and 1076 (27%, 95% CI 20% 
to 35%) of GAD-2 (yes/no) positives met criteria for 
any SCID anxiety disorder (including PTSD and OCD), 
whereas 5110 (92%, 95% CI 87% to 95%) GAD-2 (yes/
no) negatives and 2881 (73%, 95% CI 65% to 80%) 
GAD-2 (yes/no) positives had no anxiety disorders (see 
online supplementary files 5 and 7 for cross-tabulation 
and proportions). Weighted sensitivity was 0.70, speci-
ficity 0.64, PPV 0.27, NPV 0.92, LR+ 1.95 and LR− 0.46. 
The exclusion of PTSD and OCD to the group of ‘any’ 
anxiety disorders made little difference (see table 3 and 
online supplementary file 8 for cross-tabulation). Sensi-
tivity analysis of when PTSD missing data were considered 
as cases of PTSD and not cases of PTSD also did not make 
much difference (see table 3 and online supplementary 
file 9 for cross-tabulations).
DIsCussIOn
In this inner-city maternity population, the population 
prevalence estimated for GAD was 5% (95% CI 3% to 
6%) and for all anxiety disorders was 17% (95% CI 12% 
to 21%), in line with other studies.11 The population 
prevalence estimated for PTSD was lower (0.8%, 95% CI 
0% to 1%) than the mean prevalence of 3.86% reported 
in a recent systematic review of PTSD identified by inter-
views during pregnancy.27 However, as some women in 
our study who declined to answer the PTSD module also 
reported severe trauma elsewhere during the research 
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interview, we conducted a sensitivity analysis where 
missing data were assumed first to be cases of PTSD and 
then in a second analysis not to be PTSD cases: the preva-
lence estimate of PTSD was then potentially as high as 4% 
(95% CI 2% to 6%). Thus, the low prevalence of PTSD 
in our main analysis may reflect barriers to disclosure of 
trauma and associated symptoms.
As others have reported,28 29 comorbidity is also common 
and we found estimates for comorbid depression and 
GAD (2%, 95% CI 1% to 3%) that were similar to previous 
estimates derived from representative samples and using 
diagnostic clinical interviews (GAD and depression 2% 
(95% CI 0% to 3%).28 However, the population prevalence 
estimated in our sample of comorbid depression and any 
anxiety (5%, 95% CI 2% to 7%) was slightly lower than 
previous estimates (7%, 95% CI 3% to 11%).28
This study makes a novel contribution to the gap in the 
literature by formally examining the diagnostic accuracy of 
the GAD-2 screening questionnaire for women during early 
pregnancy. The GAD-2 (using a cut-off of ≥3; as recom-
mended by NICE) had a reasonable LR when used in early 
pregnancy for identifying GAD (LR+ 7, ie, above 5, which 
has been suggested to indicate a potentially useful tool in 
clinical practice).30 However, GAD is not very common and 
the PPV is low (26%). Furthermore, the diagnostic accu-
racy of the GAD-2 for identifying other anxiety disorders 
was poor (LR+ 2.92). This evidence suggests that the GAD-2 
is not a helpful tool for maternity services as it will generate 
many false positives.
There are several strengths to this study. First, we recruited 
a stratified representative sample of women using language 
interpreters to facilitate inclusion of non-English-speaking 
women.21 Second, we used an efficient and robust sampling 
design which facilitated the estimation of population prev-
alences and we used a gold standard diagnostic interview. 
Limitations include recruitment from a single maternity 
site in London, although the single South London mater-
nity site used in this study included a very ethnically and 
socioeconomically diverse population. There were some 
missing data (although this was rare other than for PTSD), 
and timing of administering the GAD-2 in early pregnancy 
may have overinflated the risk of ‘false positives’.
Implications
This study does not support the NICE recommendation 
to use the GAD-2 in early pregnancy, due to its low PPV 
even for GAD (when applying a cut-off of both ≥3 or≥1 
indicating a yes response) and low effectiveness for ‘any 
anxiety disorder’. Its accuracy later in pregnancy warrants 
further study but a recent systematic review reported the 
prevalence of self-reported anxiety symptoms to increase 
through pregnancy (trimester 1: 18%, trimester 2: 19%, 
trimester 3: 25%)11; diagnostic accuracy is therefore 
unlikely to improve.
Table 3 Sensitivity, specificity, PPV, NPV, LR+ and LR− of the GAD-2 questions (n=528)
GAD-2 cut-off GAD
Any anxiety disorders
(including PTSD and OCD) Any anxiety 
disorders
(excluding PTSD and 
OCD)*
19 missing data 
on PTSD (n=516)†
If missing cases 
considered as 
PTSD cases
If missing cases 
considered as not 
PTSD cases
Cut-off≥3
  Sensitivity 0.69 0.26 0.26 0.26 0.26
  Specificity 0.91 0.91 0.91 0.91 0.90
  PPV 0.26 0.36 0.38 0.34 0.31
  NPV 0.98 0.87 0.85 0.87 0.88
  LR+ 7.35 2.92 2.84 2.82 2.71
  LR− 0.34 0.81 0.82 0.81 0.82
Cut-off≥1 (yes/no)
  Sensitivity 1 0.70 0.70 0.70 0.68
  Specificity 0.60 0.64 0.64 0.63 0.62
  PPV 0.11 0.27 0.30 0.26 0.23
  NPV 1 0.92 0.91 0.92 0.92
  LR+ 2.53 1.95 1.95 1.90 1.81
  LR− 0 0.46 0.47 0.47 0.51
*We excluded PTSD and OCD to present the difference, as DSM-5 no longer considered PTSD and OCD as anxiety disorders.
†Nineteen participants had missing data on the PTSD module. Seven of these participants met criteria for other anxiety disorders. Therefore, 
the total sample size for any anxiety disorders was 516.
DSM-5, Diagnostic and Statistical Manual of Mental Disorders, fifth edition; GAD, Generalised Anxiety Disorder; LR, likelihood ratio; NPV, 
negative predictive value; OCD, obsessive-compulsive disorder; PPV, positive predictive value; PTSD, post-traumatic stress disorder. 
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Following the NICE CG192 guideline recommenda-
tions, some services have already implemented the GAD-2 
in routine practice. The findings from the current paper 
challenge the use of expert consensus and extrapolation 
from evidence derived from the general population to 
pregnant women when making the NICE recommen-
dations specifically for pregnant women. We argue that 
recommendations for pregnant women should be evidence 
based and propose that, at present, only the NICE recom-
mendation on use of the Whooley questions is supported 
by evidence.21 Currently, the evidence suggests that imple-
mentation of routine use of the GAD-2 is unwarranted. 
This brings us to a number of potential unexplored future 
research directions, which include a comprehensive diag-
nostic accuracy study, including data on acceptability, of 
the full GAD-7 questionnaire in pregnancy and the three 
‘anxiety’ items in the Edinburgh Postnatal Depression 
Scale in pregnancy. For the GAD-7, currently there is no 
evidence. There is some conflicting evidence for the three 
‘anxiety items’ in the Edinburgh Postnatal Depression 
Scale, but as others have suggested, research is needed to 
determine their validity, reliability and diagnostic accuracy 
as a measure of antenatal anxiety disorders.31 32 Further-
more, use of other routinely collected data including 
the Whooley questions could be used in a model (using 
predictive modelling techniques) to identify anxiety 
disorders or perhaps even more importantly, ‘any mental 
disorder’. Finally, further research is needed to examine 
ways to overcome the barriers to disclosure of trauma 
and trauma-related symptoms in pregnancy. This suggests 
that more sensitive methods need to be developed to ask 
women about trauma.
COnClusIOns
This study suggests that anxiety disorders are common in 
early pregnancy, but the GAD-2 screening measure is not 
useful during early pregnancy. In addition, even if asked 
directly, PTSD may be particularly difficult to detect in 
routine practice (as some women may decline to answer 
specific questions in relation to symptoms arising from 
traumatic experiences) and therefore further research is 
needed on how to overcome barriers to disclosure of trau-
ma-related symptoms .
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